查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016962

獸醫分子診斷市場：依產品類型、技術、動物類型、疾病類型和最終用戶分類－2026-2032年全球市場預測

Veterinary Molecular Diagnostic Market by Product, Technology, Animal Type, Disease Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸醫分子診斷市場價值將達到 13.8 億美元，到 2026 年將成長到 14.9 億美元，到 2032 年將達到 23.5 億美元，複合年成長率為 7.90%。

主要市場統計數據
基準年 2025 13.8億美元
預計年份：2026年 14.9億美元
預測年份 2032 23.5億美元
複合年成長率 (%) 7.90%

在獸醫分子診斷領域技術快速發展和運作挑戰不斷變化的背景下，為決策者提供背景資訊。

獸醫分子診斷領域正處於快速技術創新與動物醫學各領域對準確快速檢測日益成長的需求交會點。聚合酵素鏈鎖反應(PCR)、數位和等溫擴增技術、微陣列平台以及高通量定序的最新進展，拓展了檢測感染疾病病原體、識別遺傳疾病以及支持獸醫腫瘤學研究的可能性。同時，隨著終端使用者群體從學術機構和研究實驗室擴展到診斷檢查室和臨床獸醫醫院，一個更為複雜的生態系統正在形成，其中診斷方法必須具備穩健性、成本效益，並能融入臨床工作流程。

檢驗了將重塑獸醫分子診斷的開發、檢驗和交付的重要技術、監管和營運變革。

由於技術融合、臨床需求不斷變化以及供應鏈和報銷模式面臨的系統性壓力，獸醫分子診斷領域正經歷變革性的變化。次世代定序正從小眾研究應用轉向病原體發現和抗菌藥物抗藥性分析等更常規的應用，而即時PCR和數位PCR仍然是標靶、高靈敏度檢測的關鍵技術。同時，等溫擴增技術和可攜式平台正在推動水產養殖、畜牧業和野生動物監測領域的照護現場診斷和現場診斷，從而支持快速應對疫情和團隊決策。生物資訊軟體和雲端分析技術的進步進一步促進了這些變革，縮短了結果獲取時間，並使複雜分析得以廣泛應用。

分析 2025 年美國關稅措施對獸醫分子診斷供應鏈的多方面營運和採購影響。

美國2025年實施的累積關稅措施對獸醫分子診斷供應鏈、籌資策略和成本結構產生了多方面的影響。關稅導致進口設備和某些試劑價格上漲，給檢查室採購預算帶來壓力，並影響了其對昂貴設備和一次性耗材來源的決策。因此，一些檢查室和獸醫網路正在加快在地化策略的實施，例如尋求國內分銷商和區域生產合作夥伴，以降低貿易摩擦帶來的風險並避免庫存波動。

我們按產品類型、技術、動物種類、目標疾病和最終用戶環境進行詳細細分，以指導有針對性的診斷策略和開發。

對市場區隔的精準理解揭示了需求來源，闡明了技術選擇如何與動物種類和疾病重點相交織，以及哪些終端使用者環境能夠推動技術的持續應用。基於產品差異化，市場由耗材和試劑、儀器以及軟體和服務所構成。耗材和試劑包括酵素製劑、檢測試劑盒、探針和引子等，這些對於檢測的靈敏度和特異性至關重要。同時，儀器類別涵蓋了從PCR儀到定序儀等各種產品，能夠滿足不同的處理能力和應用需求。軟體和服務正日益扮演「連接組織」的角色，支援資料解讀、工作流程調整和遠距離診斷。

為了解美洲、歐洲、中東和非洲以及亞太地區的區域需求因素、基礎設施成熟度和監管多樣性，我們將利用這些資訊來制定部署策略。

區域趨勢在塑造獸醫分子診斷的需求、監管方式和應用模式方面發揮決定性作用。在美洲，成熟的獸醫服務市場、強大的研究基礎設施以及先進的畜牧和伴侶動物護理體系，推動了對高通量平台、專用試劑和整合軟體解決方案的需求，以支援臨床決策和流行病學監測。此外，該地區許多私人獸醫診所和實驗室的存在，也加速了專為伴侶動物和生產動物量身定做的新型檢測方法和伴侶診斷技術的應用。

透過儀器供應商、試劑製造商、檢測開發商和軟體服務供應商之間的競爭與夥伴關係來評估差異化。

獸醫分子診斷領域的競爭格局呈現出多元化的態勢，既有成熟的平台供應商，也有專注於特定應用和現場部署技術的敏捷型Start-Ups。儀器製造商持續投資於與開放平台的兼容性，以確保耗材和服務方面的收入來源；試劑供應商則著重推廣檢驗的試劑盒和品管樣品，以加速檢查室認證和常規應用。同時，軟體供應商和服務供應商正透過分析能力、解讀演算法和雲端報告功能來提升自身競爭力，從而減輕最終用戶（檢查室和臨床醫生）的負擔。

為產業領導者制定優先且可操作的策略，以增強韌性、加速臨床部署並擴大診斷在整個動物保健領域的影響力。

業界領導者應優先推進一系列切實可行的舉措，以增強獸醫分子診斷領域的韌性，加速技術應用，並提升其臨床影響力。首先，應設計一個注重互通性的產品系列，透過檢驗檢測方法在多個儀器平台上的適用性，並確保其與廣泛使用的資料管理系統相容。這將有助於減少採購摩擦，並擴大目標市場。其次，應投資區域性生產和策略供應商協議，以確保關鍵試劑和酵素的供應，同時實施庫存最佳化措施，以因應短期貿易中斷。

為了檢驗這些見解，我們描述了一種嚴謹的混合方法研究途徑，該方法整合了初步訪談、技術文獻和供應鏈基準。

本研究整合了定性和定量方法，以確保對獸醫分子診斷的現狀形成穩健且基於實證的理解。方法論首先是對同行評審文獻、監管指南、技術白皮書和行業出版物進行全面回顧，以確定基本定義、技術能力和檢驗標準。在此基礎上，主要調查包括對檢查室管理人員、獸醫、檢測開發人員、儀器工程師和採購專家進行結構化訪談，以收集有關工作流程、應用障礙和採購行為的實際見解。

重視技術創新、營運韌性和合作夥伴關係，以確保對診斷產生永續的影響。

獸醫分子診斷的未來發展趨勢是：技術進步、數據驅動型服務的日益融合以及採購和監管環境的變革，這些因素共同為相關人員創造了機遇，同時也帶來了責任。目前，解決方案正朝著兼顧分析性能和操作可行性的方向發展，無論採用何種技術或目標動物種類，都能在臨床護理、監測和調查中獲得更快、更準確的結果。同時，供應鏈的脆弱性和關稅相關的壓力也要求制定策略規劃，以確保檢測的連續性，並在不同的終端用戶環境中維持服務水準。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 獸醫分子診斷市場：依產品類型分類

  • 耗材和試劑
    • 酵素
    • 成套工具
    • 探針和引子
  • 裝置
    • PCR裝置
    • 序列器
  • 軟體服務

第9章：獸醫分子診斷市場：依技術分類

  • 常規PCR
  • 數位PCR
  • 等溫擴增
  • 微陣列
  • 次世代定序
    • Illumina定序
    • 離子流定序
    • 牛津奈米孔
  • 即時PCR

第10章：獸醫分子診斷市場：依動物類型分類

  • 水產養殖
    • 魚
    • 甲殼類動物
  • 鳥類
  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 豬
  • 野生動物

第11章 獸醫分子診斷市場：依疾病類型分類

  • 遺傳性疾病
  • 感染疾病
    • 細菌感染疾病
    • 黴菌感染疾病
    • 寄生蟲感染疾病
    • 病毒感染疾病
  • 腫瘤學

第12章 獸醫分子診斷市場：依最終用戶分類

  • 學術機構
  • 診斷中心
  • 測試機構
  • 研究機構
  • 獸醫醫院和診所

第13章 獸醫分子診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 獸醫分子診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 獸醫分子診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：獸醫分子診斷市場

第17章 中國：獸醫分子診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bio-Rad Laboratories, Inc.
  • Ceva Sante Animale SA
  • Eurofins Scientific SE
  • Heska Corporation
  • IDEXX Laboratories, Inc.
  • Neogen Corporation
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Vetoquinol SA
  • Zoetis Inc.
Product Code: MRR-034B50030397

The Veterinary Molecular Diagnostic Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.49 billion in 2026, with a CAGR of 7.90%, reaching USD 2.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.49 billion
Forecast Year [2032] USD 2.35 billion
CAGR (%) 7.90%

Establishing context for decision-makers amid rapid technological advances and evolving operational challenges in veterinary molecular diagnostics

The veterinary molecular diagnostics field stands at the confluence of rapid technological innovation and intensifying demand for precise, timely testing across animal health sectors. Recent advances in polymerase chain reaction modalities, digital and isothermal amplification techniques, microarray platforms, and high-throughput sequencing have broadened the possibilities for detecting infectious agents, characterizing genetic disorders, and supporting oncology in veterinary practice. Concurrently, an expanding base of end users-from academic institutions and research centers to diagnostic laboratories and clinical veterinary hospitals-has generated a more complex ecosystem where diagnostics must be robust, cost-effective, and integrated with clinical workflows.

As diagnostic capabilities evolve, stakeholders face a shifting landscape of regulatory requirements, supply chain sensitivities, and cross-sector collaborations. Instruments and consumables that once flowed predictably through established distributors are now influenced by global trade dynamics and supplier consolidation, while software and interpretive services are assuming greater importance to translate raw data into actionable clinical decisions. This introduction frames the subsequent analysis by emphasizing the need for strategic alignment between technology selection, operational capacity, and market-facing services. By situating the reader within this dynamic environment, the narrative that follows unpacks transformative trends, regulatory pressures, segmentation-driven opportunities, and recommended actions to navigate near-term disruptions and accelerate adoption across diverse animal types and care settings.

Overall, this section establishes context for decision-makers and researchers to assess risk, prioritize investments, and design interventions that leverage molecular diagnostics to improve animal health outcomes while managing operational complexity.

Examining the pivotal technological, regulatory, and operational shifts reshaping how veterinary molecular diagnostics are developed, validated, and delivered

The landscape of veterinary molecular diagnostics is undergoing transformative shifts driven by technological convergence, changing clinical expectations, and systemic pressures on supply chains and reimbursement models. Next-generation sequencing has transitioned from niche research use into more routine applications for pathogen discovery and antimicrobial resistance profiling, while real-time PCR and digital PCR remain workhorses for targeted, high-sensitivity detection. Simultaneously, isothermal amplification techniques and portable platforms are enabling point-of-care and field diagnostics for aquaculture, livestock, and wildlife surveillance, which supports faster outbreak response and herd-level decision-making. These changes are reinforced by software advances in bioinformatics and cloud-based interpretation that reduce turnaround times and democratize access to complex analyses.

Market dynamics are also being reshaped by consolidation among reagent suppliers and instrumentation providers, heightened regulatory scrutiny of diagnostic validation and data integrity, and growing pressure from end users for bundled solutions that combine assays, instruments, and interpretive services. In addition, the rising complexity of multi-species testing panels and the need for cross-platform compatibility has placed a premium on open architecture instruments and validated consumables. As a result, partnerships between assay developers, platform providers, and research institutions are becoming a strategic imperative to accelerate time-to-market and ensure clinical utility.

In short, the field is shifting from isolated technology deployments toward integrated, service-oriented models that emphasize data-driven diagnostics, operational resilience, and scalable workflows. Stakeholders that anticipate these shifts and align product development, distribution strategies, and customer support accordingly will gain competitive advantage in an increasingly sophisticated and outcome-focused veterinary healthcare market.

Analyzing the multifaceted operational and procurement consequences of United States tariff measures in 2025 on veterinary molecular diagnostics supply chains

Cumulative tariff developments originating in the United States for 2025 have introduced multifaceted impacts on the veterinary molecular diagnostics supply chain, procurement strategies, and cost structures. Tariff-induced increases on imported instruments and certain reagents have pressured laboratory procurement budgets and influenced decisions about where to source high-value capital equipment versus single-use consumables. As a consequence, some laboratories and veterinary networks have accelerated localization strategies, seeking domestic distributors or regional manufacturing partners to reduce exposure to trade friction and avoid inventory volatility.

These trade measures have also prompted buyers to reassess total cost of ownership for PCR instruments, sequencers, and ancillary automation, factoring in longer lead times, recalibrated maintenance agreements, and the potential for increased spare parts costs. For reagent-intensive workflows, tariffs on raw materials and specialty enzymes have elevated attention on supply diversification, inventory hedging, and longer contract terms with suppliers who can guarantee continuity. In parallel, software and interpretive services, which are less dependent on cross-border physical shipments, have emerged as lower-tariff avenues to add value to diagnostic offerings and to offset hardware-related cost pressures.

Regulatory and procurement teams have responded by renegotiating supplier agreements, exploring strategic partnerships with regional manufacturers, and prioritizing open-platform instruments that accept a range of validated consumables to mitigate single-supplier risk. At the same time, laboratories have increased investments in workflow efficiency and multiplexing assays to reduce per-test reagent consumption. Collectively, these responses are reshaping purchasing patterns, driving more collaborative supplier relationships, and accelerating adoption of resilient procurement practices that balance cost, performance, and supply chain security under a more protectionist trade environment.

Unpacking detailed segmentation across product, technology, animal type, disease focus, and end-user settings to guide targeted diagnostic strategies and development

A nuanced understanding of market segmentation reveals where demand originates, how technology choices intersect with animal species and disease priorities, and which end-user settings will drive sustained adoption. Based on product distinctions, the market comprises consumables and reagents, instruments, and software and services. Consumables and reagents can be understood through their enzyme formulations, assay kits, and probes and primers that are critical for assay sensitivity and specificity, while instrument categories range from PCR instruments to sequencers that serve different throughput and application needs. Software and services increasingly function as the connective tissue that enables data interpretation, workflow orchestration, and remote diagnostics.

When viewed through the lens of technology, conventional PCR, digital PCR, isothermal amplification, microarray, next-generation sequencing, and real-time PCR present differentiated value propositions. Next-generation sequencing itself spans Illumina sequencing, Ion Torrent sequencing, and Oxford Nanopore approaches, each offering distinct trade-offs in read length, throughput, and field deployability. These technology choices map closely to animal type considerations where aquaculture testing for fish and shellfish requires robust, often field-capable assays; avian applications prioritize rapid pathogen detection to protect flock health; companion animal diagnostics, particularly for cats and dogs, emphasize genetic disorder screening and oncology panels; livestock testing for cattle, poultry, and swine centers on herd-level surveillance and production-impacting infectious diseases; and wildlife testing calls for broad-spectrum pathogen discovery and conservation-focused genetic analysis.

Disease-type segmentation further refines validation and development priorities, with genetic disorders necessitating high-fidelity genotyping assays, infectious diseases demanding sensitive and rapid pathogen detection across bacterial, fungal, parasitic, and viral etiologies, and oncology requiring assays that can profile tumor-associated variants. Finally, end users-academic institutes, diagnostic centers, reference laboratories, research institutes, and veterinary hospitals and clinics-differ in throughput, regulatory expectations, and willingness to adopt complex workflows. Academic and research settings often pilot innovative technologies and bioinformatics methods, reference laboratories prioritize standardized, high-throughput assays with rigorous QC, while clinical veterinary hospitals seek integrated solutions that deliver rapid, interpretable results to inform patient care. Taken together, these segmentation dimensions provide a roadmap for product development, validation strategies, and go-to-market prioritization that align technological capabilities with the operational needs of each user cohort.

Mapping regional demand drivers, infrastructure maturity, and regulatory diversity across the Americas, Europe Middle East Africa, and Asia-Pacific to inform deployment strategies

Regional dynamics play a decisive role in shaping demand, regulatory approaches, and deployment models for veterinary molecular diagnostics. In the Americas, a mature veterinary services market, robust research infrastructure, and advanced livestock and companion animal care ecosystems drive demand for high-throughput platforms, specialized reagents, and integrated software solutions that support both clinical decision-making and epidemiological surveillance. The region's strong base of private veterinary practices and reference labs also supports early adoption of novel assays and companion diagnostics tailored to companion animals and production species.

Across Europe, the Middle East and Africa, a diversity of regulatory environments and varying levels of laboratory capacity produce a heterogeneous adoption pattern. Western and northern European markets tend to adopt high-complexity technologies with stringent validation standards, while parts of the Middle East and Africa emphasize cost-effective, field-ready diagnostics to manage transboundary animal diseases and zoonotic risks. Capacity building and public-private partnerships are accelerating molecular diagnostic deployment in several subregions, supported by collaborative initiatives that strengthen laboratory networks and data-sharing frameworks.

The Asia-Pacific region is characterized by rapidly expanding veterinary services, sizable aquaculture industries, and intensive livestock production systems that heighten demand for scalable diagnostics and surveillance tools. Countries in this region are investing in sequencing and multiplex assay capabilities to manage disease outbreaks and to enhance food safety. Regional manufacturing capability and growing local reagent supply chains are also emerging, which helps mitigate the effects of cross-border trade disruptions and supports faster turnaround times for high-volume testing needs. These regional contrasts underscore the importance of tailoring product portfolios, regulatory strategies, and distribution models to localized clinical needs, infrastructure maturity, and policy priorities.

Assessing competitive dynamics and partnership-driven differentiation among instrument providers, reagent manufacturers, assay developers, and software service vendors

Competitive dynamics in veterinary molecular diagnostics reflect a mix of established platform providers, specialized assay developers, and agile startups that focus on niche applications or field-deployable technologies. Instrument manufacturers continue to invest in open-platform compatibility to capture consumable and service revenue streams, while reagent suppliers emphasize validated kits and quality control materials that accelerate laboratory accreditation and routine use. At the same time, software vendors and service providers are differentiating through analytics, interpretive algorithms, and cloud-enabled reporting that reduce the burden on end-user laboratories and clinicians.

Collaboration remains an important strategy: co-development agreements between assay developers and instrument providers accelerate validation cycles and enable bundled offerings that appeal to diagnostic centers and reference laboratories. Partnerships with academic institutions and research institutes often underpin innovation in assay design and bioinformatics pipelines, producing early-stage validation data that de-risks commercial launches. Startups focusing on point-of-care and portable sequencing are attracting attention for their potential to decentralize testing in aquaculture, livestock field surveillance, and wildlife monitoring, prompting strategic responses from incumbents seeking to fortify their product pipelines.

Finally, differentiation through quality, regulatory compliance, and customer support is increasingly significant. Buyers prioritize partners who can provide comprehensive training, robust QC materials, and rapid service response to minimize downtime. Companies that invest in lifecycle services, remote troubleshooting, and evidence-backed performance claims are better positioned to secure long-term contracts with diagnostic centers and veterinary hospital networks. In this competitive landscape, thoughtful alliance-building, clear validation pathways, and a focus on end-user experience determine which organizations capture the most durable value.

Prioritized, practical strategies for industry leaders to enhance resilience, accelerate clinical adoption, and expand diagnostic impact across animal health sectors

Industry leaders should pursue a set of practical, prioritized actions to strengthen resilience, accelerate adoption, and support clinical impact in veterinary molecular diagnostics. First, design product portfolios with interoperability in mind by validating assays across multiple instrument platforms and ensuring compatibility with widely used data management systems; this reduces procurement friction and expands addressable markets. Second, invest in regional manufacturing and strategic supplier agreements to secure critical reagents and enzymes, while implementing inventory optimization techniques to buffer short-term trade disruptions.

Third, align regulatory and clinical validation strategies to the needs of target end users by generating robust performance data for prioritized disease panels and species-specific indications. Engage early with reference laboratories and academic partners to co-develop evidence packages that facilitate adoption in diagnostic centers and clinical settings. Fourth, enhance service offerings by bundling software, interpretive analytics, and training programs that lower the operational barriers for veterinary hospitals and clinics adopting molecular diagnostics. Fifth, adopt modular go-to-market models that pair high-throughput reference lab solutions with scaled-down, field-capable platforms for aquaculture, livestock, and wildlife surveillance.

Finally, prioritize data governance, cybersecurity, and interoperability standards when designing cloud-based reporting systems, and maintain transparent communication about validation, quality control, and supply chain provenance. By executing these targeted actions, companies can reduce commercial friction, support evidence-based adoption, and create durable partnerships with laboratories and clinical networks that accelerate the uptake of molecular diagnostics across animal health domains.

Describing a rigorous mixed-methods research approach that synthesizes primary interviews, technical literature, and supply chain benchmarking to validate insights

This research integrates qualitative and quantitative methods to ensure a robust, evidence-based understanding of the veterinary molecular diagnostics landscape. The methodological approach began with a comprehensive review of peer-reviewed literature, regulatory guidance, technical white papers, and industry publications to establish baseline definitions, technology capabilities, and validation criteria. Building on this foundation, primary research included structured interviews with laboratory directors, veterinary clinicians, assay developers, instrument engineers, and procurement specialists to capture practical insights on workflow, adoption barriers, and purchasing behavior.

Additionally, a systematic mapping of product and technology segmentation was performed to align consumable categories, instrument classes, and software offerings with species-specific and disease-focused use cases. Cross-validation exercises compared primary insights with secondary sources and subject matter expert feedback to reconcile divergent perspectives and ensure internal consistency. Analytical techniques included thematic synthesis for qualitative inputs, workflow and use-case benchmarking to assess operational fit, and supply chain analysis to identify risk nodes and mitigation strategies.

Limitations are acknowledged: evolving trade policy, rapid platform innovations, and localized regulatory shifts can change dynamics after data collection, so stakeholders should treat findings as a decision-support framework rather than a static prediction. To support transparency, the methodology documents sources of primary data, interviewee profiles, and validation steps to allow readers to assess the applicability of specific findings to their contexts. This mixed-methods approach provides a defensible basis for strategic decisions, product planning, and regulatory engagement in the veterinary molecular diagnostics domain.

Concluding synthesis that emphasizes aligning technological innovation, operational resilience, and collaborative partnerships to realize durable diagnostic impact

The trajectory of veterinary molecular diagnostics is characterized by growing technical sophistication, heightened integration of data-driven services, and evolving procurement and regulatory landscapes that together create both opportunities and responsibilities for stakeholders. Across technologies and animal types, there is a clear movement toward solutions that balance analytical performance with operational feasibility, enabling faster, more accurate outcomes for clinical care, surveillance, and research. At the same time, supply chain vulnerabilities and tariff-related pressures necessitate strategic planning to ensure continuity of testing and maintain service levels across diverse end-user environments.

Consequently, organizations that invest in interoperable platforms, diversified supply chains, and evidence-led validation will be best positioned to support the expanding role of molecular diagnostics in veterinary medicine. Equally important is the commitment to end-user training, quality assurance, and data stewardship to translate analytical gains into improved animal health outcomes. The conclusion synthesizes the core message: sustainable progress depends on aligning technological innovation with pragmatic deployment strategies, robust partnerships, and adaptive procurement practices that together enable scalable, high-quality diagnostic services across the full spectrum of veterinary care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Molecular Diagnostic Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes
    • 8.1.2. Kits
    • 8.1.3. Probes & Primers
  • 8.2. Instruments
    • 8.2.1. PCR Instruments
    • 8.2.2. Sequencers
  • 8.3. Software & Services

9. Veterinary Molecular Diagnostic Market, by Technology

  • 9.1. Conventional PCR
  • 9.2. Digital PCR
  • 9.3. Isothermal Amplification
  • 9.4. Microarray
  • 9.5. Next-Generation Sequencing
    • 9.5.1. Illumina Sequencing
    • 9.5.2. Ion Torrent Sequencing
    • 9.5.3. Oxford Nanopore
  • 9.6. Real-Time PCR

10. Veterinary Molecular Diagnostic Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shellfish
  • 10.2. Avian
  • 10.3. Companion Animals
    • 10.3.1. Cats
    • 10.3.2. Dogs
  • 10.4. Livestock
    • 10.4.1. Cattle
    • 10.4.2. Poultry
    • 10.4.3. Swine
  • 10.5. Wildlife

11. Veterinary Molecular Diagnostic Market, by Disease Type

  • 11.1. Genetic Disorders
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Parasitic Infections
    • 11.2.4. Viral Infections
  • 11.3. Oncology

12. Veterinary Molecular Diagnostic Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Diagnostic Centers
  • 12.3. Reference Laboratories
  • 12.4. Research Institutes
  • 12.5. Veterinary Hospitals & Clinics

13. Veterinary Molecular Diagnostic Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Molecular Diagnostic Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Molecular Diagnostic Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Veterinary Molecular Diagnostic Market

17. China Veterinary Molecular Diagnostic Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bio-Rad Laboratories, Inc.
  • 18.6. Ceva Sante Animale S.A.
  • 18.7. Eurofins Scientific SE
  • 18.8. Heska Corporation
  • 18.9. IDEXX Laboratories, Inc.
  • 18.10. Neogen Corporation
  • 18.11. QIAGEN N.V.
  • 18.12. Thermo Fisher Scientific Inc.
  • 18.13. Vetoquinol S.A.
  • 18.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 258. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 262. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 266. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 268. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFEC